Insights into the specific feature of the electrostatic recognition binding mechanism between BM2 and BM1: a

Guixuan Xing1, Qingchuan Zheng2,1

  • 1Institute of Theoretical Chemistry, College of Chemistry, Jilin University, Changchun 130023, China.

Insights

Interactions between influenza B virus matrix proteins BM2 and BM1 are crucial for viral replication. This study reveals key polar residues stabilizing their binding, offering insights for antiviral drug design.

Area of Science:

  • Virology
  • Structural Biology
  • Computational Biology

Background:

  • Matrix protein 2 (BM2) and matrix protein 1 (BM1) are essential components of the influenza B virus.
  • Their interactions are vital for virus assembly and replication, but atomic-level details remain elusive.

Purpose of the Study:

  • To elucidate the atomic-level binding mechanism between influenza B virus BM2 and BM1 proteins.
  • To identify key residues involved in the BM2-BM1 interaction and their role in viral processes.
  • To provide a foundation for designing novel anti-influenza therapeutics.

Main Methods:

  • Homology modeling and molecular docking were employed to construct the BM2-BM1 complex.
  • Molecular dynamics (MD) simulations were utilized to analyze the binding mechanism.
  • Site-directed mutagenesis experiments were performed to validate simulation findings.

Main Results:

  • Eight polar residues (E88B, E89B, H119BM1, E94B, R101BM1, K102BM1, R105BM1, E104B) were identified as critical for stabilizing the BM2-BM1 interaction via hydrogen bonds and salt bridges.
  • Mutations affecting these polar residues disrupted the BM2-BM1 complex, impacting viral assembly and replication.
  • Both effector domain and non-effector domain mutations demonstrated significant effects.

Conclusions:

  • The study provides a detailed atomic-level understanding of the BM2-BM1 interaction in influenza B virus.
  • Key polar residues and their interactions are crucial for maintaining viral integrity and function.
  • These findings offer valuable targets for the development of new anti-influenza drugs.